Rebekah J Nicholson1, Annelise M Poss1, J Alan Maschek2, James E Cox2, Paul N Hopkins3, Steven C Hunt3,4, Mary C Playdon1,5, William L Holland1, Scott A Summers1. 1. Department of Nutrition and Integrative Physiology, and the Diabetes and Metabolism Research Center, University of Utah, Salt Lake City, UT 84112, USA. 2. Department of Biochemistry, Metabolomics and Proteomics Core Research Facility, University of Utah, Salt Lake City, UT 84112, USA. 3. Department of Internal Medicine, University of Utah, Salt Lake City, UT 84112, USA. 4. Department of Genetic Medicine, Weill Cornell Medicine, Doha, Qatar. 5. Division of Cancer Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT 84112, USA.
Abstract
CONTEXT: Genome-wide association studies have identified associations between a common single nucleotide polymorphism (SNP; rs267738) in CERS2, a gene that encodes a (dihydro)ceramide synthase that is involved in the biosynthesis of very-long-chain sphingolipids (eg, C20-C26) and indices of metabolic dysfunction (eg, impaired glucose homeostasis). However, the biological consequences of this mutation on enzyme activity and its causal roles in metabolic disease are unresolved. OBJECTIVE: The studies described herein aimed to characterize the effects of rs267738 on CERS2 enzyme activity, sphingolipid profiles, and metabolic outcomes. DESIGN: We performed in-depth lipidomic and metabolic characterization of a novel CRISPR knock-in mouse modeling the rs267738 variant. In parallel, we conducted mass spectrometry-based, targeted lipidomics on 567 serum samples collected through the Utah Coronary Artery Disease study, which included 185 patients harboring 1 (n = 163) or both (n = 22) rs267738 alleles. RESULTS: In-silico analysis of the amino acid substitution within CERS2 caused by the rs267738 mutation suggested that rs267738 is deleterious for enzyme function. Homozygous knock-in mice had reduced liver CERS2 activity and enhanced diet-induced glucose intolerance and hepatic steatosis. However, human serum sphingolipids and a ceramide-based cardiac event risk test 1 score of cardiovascular disease were not significantly affected by rs267738 allele count. CONCLUSIONS: The rs267738 SNP leads to a partial loss-of-function of CERS2, which worsened metabolic parameters in knock-in mice. However, rs267738 was insufficient to effect changes in serum sphingolipid profiles in subjects from the Utah Coronary Artery Disease Study.
CONTEXT: Genome-wide association studies have identified associations between a common single nucleotide polymorphism (SNP; rs267738) in CERS2, a gene that encodes a (dihydro)ceramide synthase that is involved in the biosynthesis of very-long-chain sphingolipids (eg, C20-C26) and indices of metabolic dysfunction (eg, impaired glucose homeostasis). However, the biological consequences of this mutation on enzyme activity and its causal roles in metabolic disease are unresolved. OBJECTIVE: The studies described herein aimed to characterize the effects of rs267738 on CERS2 enzyme activity, sphingolipid profiles, and metabolic outcomes. DESIGN: We performed in-depth lipidomic and metabolic characterization of a novel CRISPR knock-in mouse modeling the rs267738 variant. In parallel, we conducted mass spectrometry-based, targeted lipidomics on 567 serum samples collected through the Utah Coronary Artery Disease study, which included 185 patients harboring 1 (n = 163) or both (n = 22) rs267738 alleles. RESULTS: In-silico analysis of the amino acid substitution within CERS2 caused by the rs267738 mutation suggested that rs267738 is deleterious for enzyme function. Homozygous knock-in mice had reduced liver CERS2 activity and enhanced diet-induced glucose intolerance and hepatic steatosis. However, human serum sphingolipids and a ceramide-based cardiac event risk test 1 score of cardiovascular disease were not significantly affected by rs267738 allele count. CONCLUSIONS: The rs267738 SNP leads to a partial loss-of-function of CERS2, which worsened metabolic parameters in knock-in mice. However, rs267738 was insufficient to effect changes in serum sphingolipid profiles in subjects from the Utah Coronary Artery Disease Study.
Authors: Yael Pewzner-Jung; Hyejung Park; Elad L Laviad; Liana C Silva; Sujoy Lahiri; Johnny Stiban; Racheli Erez-Roman; Britta Brügger; Timo Sachsenheimer; Felix Wieland; Manuel Prieto; Alfred H Merrill; Anthony H Futerman Journal: J Biol Chem Date: 2010-01-28 Impact factor: 5.157
Authors: Magdalene K Montgomery; Simon H J Brown; Xin Y Lim; Corrine E Fiveash; Brenna Osborne; Nicholas L Bentley; Jeremy P Braude; Todd W Mitchell; Adelle C F Coster; Anthony S Don; Gregory J Cooney; Carsten Schmitz-Peiffer; Nigel Turner Journal: Biochim Biophys Acta Date: 2016-08-31
Authors: Jonathan J Petrocelli; Alec I McKenzie; Ziad S Mahmassani; Paul T Reidy; Gregory J Stoddard; Annelise M Poss; William L Holland; Scott A Summers; Micah J Drummond Journal: J Gerontol A Biol Sci Med Sci Date: 2020-09-16 Impact factor: 6.053
Authors: Ngak-Leng Sim; Prateek Kumar; Jing Hu; Steven Henikoff; Georg Schneider; Pauline C Ng Journal: Nucleic Acids Res Date: 2012-06-11 Impact factor: 16.971